Twitxy Saved

Bobby Koneru, MD

Verified account This account is verified. Learn more

@KoneruMd

Radiation Oncologist, Father of 4, Avid Tenns fan 🎾. Northwestern University Alumni. Passion for Musculoskeletal conditions and Prostate Cancer.
Freeport, IL podcasts.apple.com/us/podcast/the… Joined December 2020
988 Following 2.7K Followers 991 Posts

Latest posts 5

Pinned post

Bobby Koneru, MD Verified account @KoneruMd
I’m excited to share that our publication of the first modern American case series for the treatment of Osteoarthritis (OA) with Low Dose Radiotherapy (LDRT) is now published and available online in the red journal.

The American patient population differs significantly from European and Asian populations in terms of obesity prevalence, dietary patterns, and lifestyle factors. This paper is the first of its kind to report an American patient population treated with LDRT utilizing modern field design, dosing, and treatment schedules allowing for a second course.

I would like to thank @WilliamSmallJr and @DrRShaffer for their guidance.

Our program at FHN has now treated over 250 OA patients over the past 2 years. I’m inspired everyday by the impact LDRT has done for our community and patients.

Article link: redjournal.org/article/S0360-…
8 replies 39 reposts 139 likes 14K views View on X
Bobby Koneru, MD Verified account @KoneruMd
Behind the scenes today at the JointGLOW studio, filming a new series of educational videos focused on musculoskeletal anatomy, physical examination, and clinical assessment.

From the cervical spine to the knees, hips, shoulders, hands, and feet, we’re building a comprehensive educational library to support future JointGlow certification and training programs.
Bobby Koneru, MD Verified account @KoneruMd
Thrilled to share that the The American Radium Society (ARS) Benign Committee has just published our new Appropriate Use Criteria (AUC) on Low-Dose Radiotherapy for the Treatment of Inflammatory Periarticular Disorders, covering conditions such as plantar fasciitis, shoulder tendinopathy, and greater trochanteric pain syndrome.

As Vice Chairman of the committee, I am incredibly proud of the dedication, quality, and momentum our team has maintained over the past six months.

A special thank you to Suzanne Russo and Austin Dove for their exceptional leadership throughout this initiative, and huge congratulations to Austin Kirschner, MD, PhD for leading this particular publication to completion!
Bobby Koneru, MD Verified account @KoneruMd
This felt like more than a presentation. It felt like a moment for the field.

This week at ASTRO, I had the privilege of presenting the long-term results of a randomized trial evaluating low-dose radiotherapy for knee osteoarthritis. Nearly 300 patients. Almost 12 years of follow-up. And importantly, the story extended beyond pain relief: the patient-reported improvements aligned with MRI findings showing less structural deterioration and long-term clinical outcomes showing lower rates of disability, with particularly encouraging findings in patients with Grade 2 disease.

I am incredibly grateful to be a co-author on this work with Makarova and an extraordinary international team of investigators, including Richard Shaffer, David Barron, Evan Thomas, Sayed, Heinrich Seegenschmiedt and many others who have spent years advancing our understanding of functional radiotherapy.

Science moves forward because people are willing to ask questions that may challenge conventional thinking—and then do the difficult work required to answer them.

I also want to thank ASTRO for giving this research such an important platform: selecting it for the Clinical Trials session, including it in the official press program, and helping bring this conversation to physicians, scientists, patients and the wider world.

But this cannot be the finish line.

My next mission is to help build the definitive multicenter, randomized, sham-controlled trial to confirm these findings. A trial designed prospectively around the questions that now matter most: patient selection, imaging, durability, disability, joint replacement and long-term safety.

That work is already underway.

If these findings are confirmed, we may eventually look back at this period as the point when radiotherapy began to be viewed not simply as a treatment for cancer, but as a broader tool for modifying disease and preserving function.

The first study opened the door. Now we have to walk through it.

#ASTRO2026 #RadiationOncology #Osteoarthritis #LDRT #FunctionalRadiotherapy #ClinicalTrials #Research #Innovation
1 replies 14 reposts 58 likes 4.8K views View on X
Bobby Koneru, MD Verified account @KoneruMd
Looking forward to Boston and ASTRO 2026.

Over the past 20 years in radiation oncology, some of the most meaningful parts of this specialty have been the friendships, collaborations, and connections built along the way. I’m excited to reconnect with colleagues and friends from across the field and to meet many new ones.

I’ll be participating in several events throughout the meeting:

• Saturday: Panel discussion at the Functional Radiotherapy Meeting
• Sunday: Presenting during the Clinical Trials Session, followed later by time at the XSTRAHL booth
• Monday: Meet the Experts at the CQ Medical booth
• Tuesday: Meet the Experts with Varian

If you’ll be at ASTRO, please stop by and say hello. I’m looking forward to the science, the conversations, and especially the opportunity to reconnect with so many people who have made this specialty such a rewarding community.

See you in Boston!

#ASTRO2026 #RadiationOncology #FunctionalRadiotherapy #ClinicalTrials #CancerCare #MedicalPhysics #Radiotherapy